Enanta Pharmaceuticals, Inc. (ENTA)

Enanta's stock price surged by 81.60% over the past six months and 160.69% over the past year, despite recent volatility. In December 2025, Enanta's Chief Business Officer, Brendan Luu, sold 1,394 shares of common stock. In November 2025, the company's stock touched a 52-week low of $6.36 amid market challenges, though analysts maintained positive ratings due to pipeline potential. Positive Phase 2b results for zelicapavir in high-risk adult outpatients with RSV were announced in September 2025. In December 2024, Enanta announced its plan to appeal a U.S. District Court ruling that found its '953 patent, related to Pfizer's COVID-19 antiviral Paxlovid™, invalid. The company reported a narrower-than-expected fourth-quarter loss in November 2024, with a decrease in research and legal expenses, despite revenue slightly below consensus estimates. In February 2025, Enanta reported its fiscal first-quarter results, showing a decrease in royalty revenue from MAVYRET/MAVIRET due to declining sales.

Demand for Enanta Pharmaceuticals' products can exhibit seasonality, particularly for its Respiratory Syncytial Virus (RSV) programs. Clinical trials for RSV treatments, such as zelicapavir, are influenced by the "Northern Hemisphere RSV season," indicating that the prevalence and demand for RSV-related treatments are higher during specific times of the year. For MAVYRET/MAVIRET, which generates royalty revenue for Enanta, no specific seasonality of demand is explicitly mentioned, but its sales are subject to competition from other HCV therapies and pricing pressures.

Enanta Pharmaceuticals is a clinical-stage biotechnology company focused on discovering and developing small molecule drugs for viral infections and immunological diseases, operating within the Health Care sector, specifically in the Biotechnology: Pharmaceutical Preparations industry. Enanta's business centers on creating oral drugs, with a strong emphasis on virology and immunology, and their pipeline includes several clinical candidates targeting various diseases. Glecaprevir, a protease inhibitor discovered by Enanta, is a component of AbbVie's combination regimens for chronic hepatitis C virus (HCV) infection. EDP-514 is a core inhibitor in Phase 1b clinical development for the treatment of chronic Hepatitis B virus (HBV). Zelicapavir (EDP-938) is an N-protein inhibitor for Respiratory Syncytial Virus (RSV), currently in Phase 3 enabling activities. EDP-323 is an L-protein inhibitor for RSV, which demonstrated significant reductions in viral load and clinical symptoms in a Phase 2a challenge study. EDP-235 is a 3CL protease inhibitor targeting human coronaviruses, including COVID-19. Enanta is expanding into immunology with programs targeting inflammatory diseases by inhibiting KIT, STAT6, and MRGPRX2, including EDP-978 (a KIT inhibitor) and EPS-3903 (a STAT6 inhibitor).

Enanta Pharmaceuticals, Inc. is headquartered in Watertown, Massachusetts, United States.

Enanta Pharmaceuticals generally holds a positive brand reputation among analysts, with a consensus rating of "Moderate Buy" or "Strong Buy" and an average price target suggesting significant upside potential. The company's progress in its RSV and immunology pipelines, including positive clinical trial results for zelicapavir and EDP-323, has contributed to this positive sentiment. However, the U.S. District Court ruling in December 2024, which found Enanta's '953 patent invalid in a lawsuit against Pfizer, could potentially impact its reputation, although Enanta plans to appeal.

Enanta Pharmaceuticals, Inc. is primarily owned by institutional shareholders (65.80%) and company insiders (49.20%), with a smaller percentage held by retail investors. Major institutional owners include Farallon Capital Management LLC, Krensavage Asset Management, LLC, Janus Henderson Group Plc, Vanguard Group Inc, BlackRock, Inc., Millennium Management Llc, Acadian Asset Management Llc, Commodore Capital Lp, VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, and IWM - iShares Russell 2000 ETF. The largest individual Enanta Pharmaceuticals shareholder is Helmut Schuhsler, owning 19.96% of the company's shares.